also known as gastric inhibitory peptide) and GLP-1 (glucagon-like peptide-1)
A 2009 research published in the Gastroenterology scientific journal indicated that gastroparesis is relatively rare, affecting just one in every 100,000 individuals (Jung HK, Choung RS, Locke GR III, et al
Exenatide versus glibenclamide in patients with diabetes
By understanding the potential side effects and monitoring your heart health, you can safely and effectively utilize this medication
doi: 10.1186/s12967-025-06856-x
Another cohort study examined tirzepatide compared to semaglutide and found the absolute difference in weight loss between the two to be 4.3% at six months and 6.9% at 12 months, meaning tirzepatide led to 4.3-6.9% greater weight loss overall